Difference between revisions of "Team:BGU Israel"
| Line 138: | Line 138: | ||
padding-top:10px; | padding-top:10px; | ||
} | } | ||
| − | .navbar | + | .navbar-brand { |
| − | + | padding: 0px; | |
| − | } | + | } |
| + | .navbar-brand>img { | ||
| + | height: 100%; | ||
| + | padding: 0 0 10px 20px; | ||
| + | width: auto; | ||
| + | } | ||
.navbar-nav li a:hover, .navbar-nav li.active a { | .navbar-nav li a:hover, .navbar-nav li.active a { | ||
color: #0186ac !important; | color: #0186ac !important; | ||
Revision as of 09:48, 29 July 2018
Abstract
Recent research studies of Amyotrophic Lateral Sclerosis (ALS) suggest that brain cells that have become toxic, directly contribute to the progression of the disease. These cells change their gene expression pattern and possess distinguishing genetic markers. In addition, they drive the death of other cells in the brain among them the motor neurons.
Our objective, as the BGU-IGEM team OriginALS, is to prolong survival of ALS patients via a novel genetic engineering approach. In order to reach this objective, we combine two separate strategies as our therapeutic approach:
- We identify and selectively eliminate only the toxic cells. In order to identify and target the toxic-cells only, we use distinguishing markers that are unique only to them.
- We prevent the generation of new toxic cells by genetically targeting specific molecules that generate the toxic cells.
In conclusion, our approach combines an apoptotic destruction of toxic cells with the prevention of the formation of new toxic cells, thus aiming to significantly reduce the occurrence of toxic cells in the central neuronal system (CNS), which is aimed at a significant deceleration of the progression rate of ALS.